Arcutis Biotherapeutics, Inc. (ARQT) Tops Q3 EPS by 15c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q3 EPS of $0.06, $0.15 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $99.2 million versus the consensus estimate of $86.99 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip
• Benchmark Reiterates Buy Rating on NVIDIA (NVDA) Following Earnings
• Snail Games unveils new titles and content updates at Gamescom 2026